Recent advances in vascular tissue engineering have led to the development of cell-free grafts that are available off-the-shelf for on demand surgery. Challenges associated with cell-based technologies including cell sourcing, cell expansion and long-term bioreactor culture motivated the development of completely cell-free vascular grafts. These are based on decellularized arteries, decellularized cultured cell-based tissue engineered grafts or biomaterials functionalized with biological signals that promote in situ tissue regeneration. Clinical trials undertaken to demonstrate the applicability of these grafts are also discussed. This comprehensive review summarizes recent developments in vascular graft technologies, with potential applications in coronary artery bypass procedures, lower extremity bypass, vascular injury and trauma, congenital heart diseases and dialysis access shunts, to name a few.
INTRODUCTION
Cardiovascular disease is the leading cause of death in the United States, claiming over 600,000 lives annually, according to the CDC-NCHS Report on Heart Disease (published February 2015). Coronary heart disease is the most prevalent among cardiovascular ailments, which is caused by blockages in major arteries around the heart, leading to heart attack or stroke 1 . Th e current eff ective remedy is an autologous transplant of saphenous vein (SV), radial artery (RA) or internal mammary artery (IMA) to the site of blockage, creating a bypass to restore normal blood cardiac fl ow. However, a number of complications and comorbidities such as hypertension, diabetes, or previous bypass or shunt procedures, especially in the elderly, can lead to unavailability of suitable autologous tissue options for graft ing procedures 1 . Th is necessitates the development of alternative technologies such as tissue engineered blood vessels (TEBVs) that may be available in a cost-eff ective, timely and reproducible manner [2] [3] [4] . Many of the challenges facing the fi eld have been overcome, particularly over the last decade, and successful TEBVs have been tested in animal models and a few human clinical trials are also underway 5, 6 . However, the current state of tissue engineering requires extensive cell culture, bioreactor preconditioning and utilization of biomaterials that do not integrate within the host vasculature 3, 7 .
TEBVs in all studies imitate the architecture of native vessels, which consist of an inner endothelium in the lumen and circumferentially aligned contractile smooth muscle layers in an extracellular matrix (ECM) media, which provides mechanical strength. Th e inner endothelium not only prevents thrombosis, but is also responsible for maintaining and altering vascular tone to control blood fl ow. Smooth muscle is present in the medial layers of the vessels, along with collagen and elastin fi bers which provide mechanical support. Smooth muscle cells (SMCs) possess contractile function and are required to expand and contract with blood fl ow, and produce ECM to replenish the degraded fi bers. Th e smooth muscle in veins and arteries vary not only in thickness, but also in homogeneity and fi ber alignment 8 . Th e more longitudinal fi ber alignment in veins make them more distensible, and has been suggested that this makes them more prone to hyperplasia when used as replacement graft s 8, 9 . In addition to function and structure, arteries and veins exhibit signifi cantly diff erent mechanical properties. In particular, the SV has a mean burst pressure of 1600 mm Hg while the IMA can withstand up to 3200 mm Hg 9 . TEBVs, in various studies reported here, are constructed to withstand pressures in similar ranges as the major arteries.
A TEBV is required to possess the following characteristics in order to function properly as a bypass graft : lack of thrombogenicity; ability to integrate into the host vasculature; and suffi cient mechanical strength. Th e gold standard still remains to be the autologous SV graft , which possesses a pre-formed endothelium and does not induce an immunogenic response. Th at being said, the main challenge facing venous bypass graft s is occlusion 10 . Indeed, an endothelium may not be easily acclimated to high arterial shear stress and if removed, it may take months to reform a confl uent healthy monolayer 11, 12 . To overcome this problem, many studies have employed a pre-formed endothelial lining while utilizing synthetic graft materials, which provides a favorable blood-material interface 13, 14 . Indeed, in a 9-year follow-up of implanted polytetrafl uoroethylene graft s in human patients, 65% of endothelialized graft s remained patent, while 16% occluded 15 . Th is study utilized fi brin glue to coat the PTFE graft s to enable endothelial cell attachment, but these graft s do not promote cell attachment, spreading or growth. Th is revealed that the confl uent endothelial layer is one of the largest contributor to patency. Nonetheless, many preclinical studies have reported rapid endothelialization especially in porcine and canine models. Th is is attributed to trans-anastomotic endothelial migration, a phenomenon that is known not to occur in humans. Trans-anastomotic endothelialization may be the biggest contributor to patency in pigs and dogs, and one must be careful in extrapolating the results obtained from these animal models to human physiology [16] [17] [18] . Human endothelialization occurs by intimal hyperplasia over suture sites that create a pannus, but pannus outgrowth is very slow -limited to about 3-5 mm in a year 11 . On the other hand, the ovine model is very similar to humans, exhibiting limited trans-anastomotic endothelial migration as well as similar primary hemostasis and coagulation patterns 19 . Th e main diff erences lie in secondary hemostasis, which for sheep is characterized by rapid initiation of contact activation, higher levels of protein C and FVIII, and higher clot fi rmness, thereby providing a stringent model for assessment of thrombogenesis 19 .
Furthermore, TEBV need to be manufactured in a time and costeff ective fashion. Th e recent trends in tissue engineering are focused on the development of off -the-shelf options that may also be customizable. Th is mandates the advances in cell-free technologies, which utilize natural or synthetic matrices that are functionalized to be anti-thrombotic and self-healing promote in situ cellular infi ltration upon implantation. Th e next generation graft s expected from tissue engineering will be capable of standard hospital storage, cause no immune response or complications in the host and most importantly, be readily available for on demand surgeries. Th is review focuses on the latest developments in such cell-free vascular graft s.
RECENT BREAKTHROUGHS IN TISSUE ENGINEERING
Th e fi rst constructed TEBV by Weinberg and Bell in 1986 utilized a Dacron mesh with circumferentially aligned SMCs and fi broblasts forming the vascular wall and an endothelial lining to prevent clotting 20 . Th e burst pressure was proportional to the collagen content, as expected, and the graft was able to integrate into the host vasculature. Th e major challenges facing this graft included lack of elastin, a major contributor to the elasticity of the vascular wall, and limited host cell infi ltration into the graft , which was restricted to the anastomoses sites 7, 20 . Nevertheless, this study laid the foundation for the fi eld of vascular tissue engineering.
Attempts with cell-based grafts
SMCs were originally obtained from host vasculature and cultured into scaff olds, or grown as cell sheets, which produced their own ECM [21] [22] [23] . Th e main challenge facing this approach was the limited cell growth, which slowed down the process of TEBV manufacture. Attempts were made to regain the replicative potential while maintaining the SMC properties, by overexpression of hTERT (human telomerase reverse transcriptase) to reverse the eff ects of cultural senescence 24, 25 . Th is enabled isolation and culture of vascular SMCs even from aged patients 25 but the tumorigenic potential of hTERT expressing cells prevents clinical application of this approach. Recently, our group identifi ed a transcription factor, Nanog, that could reverse senescence to restore SMC functionality in aged cells 26 . However, due to complications arising from genetic manipulations, SMCs were replaced by other sources, such as MSCs and fi broblasts, which were capable of producing smooth muscle proteins and ECM, and exerting contractile force 27, 28 . Fibroblasts were very eff ective in production of ECM in bioreactors, yielding TEBVs with high burst pressures 29 . Co-cultures of SMCs and fi broblasts in fi brin scaff olds have been utilized in another study, where bioreactor preconditioning resulted in an aligned, diff erentiated, functional SMC layer within 30 days 30 . An interesting technique called "biotubes" also proved eff ective, where silicone tubes were inserted into subcutaneous pouches of rabbits, and allowed to be infi ltrated with host fi broblasts which deposited ECM. Th ese cellularized biotubes were then explanted from the subcutaneous patches and implanted as autologous vascular graft s 31, 32 . Although these graft s were patent, two surgeries were required on the patient, which made mesenchymal stem cells (MSCs) the more attractive option.
Interestingly, we reported that as compared to vascular SMC, αSMAexpressing bone marrow MSC exhibited signifi cantly higher elastogenic potential in vitro and in vivo 33, 34 . Tissue engineered blood vessels that were prepared from these cells were implanted them into the jugular veins of lambs, where they remained patent and exhibited high amounts of elastin that was organized in a fi brillar network very similar to native vessels 35 . Niklason's group has also employed bone marrow MSCs in the preparation of TEVG (Tissue Engineered Vascular Graft ) that were preconditioned in a bioreactor to yield robust implantable vascular graft s 27 . Another study demonstrated that EGFP-labeled MSCs, when seeded onto polyurethane scaff olds and implanted to Wistar rats, were able to proliferate and stained positive for SMC proteins aft er just 2 weeks in vivo 28 . Both SMC-like and EC (endothelial cell)-like cells were generated from bone-marrow derived MSCs and cultured onto decellularized native scaff olds, which performed very well as interpositional graft s in ovine carotid artery implantations 36 .
Th e need for the presence of SMC in the vascular wall was challenged by a recent study from our group that compared vascular graft s with or without SMC. We concluded that the presence of SMCs in the medial layer was not necessary for successful implantation and remodeling of small intestinal submucosa (SIS)-fi brin composite vascular graft s in the arterial circulation of an ovine animal model 37 . Infi ltration of highly proliferative host SMCs into the composite biomaterial and subsequent maturation into a smooth muscle phenotype rendered the initial donor SMCs redundant, especially aft er longer times in vivo (3 months), suggesting a simplifi ed TEVG design with no cells in the vascular wall. Indeed, several implantation studies have been performed in large animal models where smooth muscle medial layer was not a contributor of patency or overall performance [38] [39] [40] . However, it was discovered that the presence of MSCs was an important contributing factor in the infl ammatory response that may be required for vascular graft healing 41, 42 .
However, endothelial cells are still required to populate the lumen of SIS-based vascular grafts to prevent thrombus formation, as we demonstrated using an ex vivo arteriovenous shunt model 43 . ECs on several biomaterial graft s are known to prevent occlusion and enhance graft patency 14 . Endothelial lining enhances patency in Dacron graft s implanted in a canine model 16 . Using endothelial cells in "bio-ink", conduits or hydrogels (for microvasculature studies) in the lumen via thermal inkjet printing technique facilitated obtaining a confl uent endothelium 44, 45 . Bioink enabled use of printer cartridges fi lled with liquid cell suspensions, which could be programmed in patterns on surfaces. However, sources for endothelial cells are limited, and the yield from autologous skin biopsies are usually insuffi cient. Th e isolation oft en needs to be followed by FACS (Fluorescence assisted cell sorting), selection media and expansion up to several passages to obtain suffi cient cell numbers 46 .
Host circulating endothelial progenitor cells (EPCs) can be isolated, cultured and employed in TEBVs, which were shown to have lesser intimal hyperplasia as compared to autologous vein graft s 39 . Although EPCs are more readily expandable in culture than mature endothelial cells, they are rather scarce in circulation, around 50 cells in 1 mL of blood 47, 48 . In order to overcome this issue, several attempts are being made to capture the EPC from the host directly using growth factor, VEGF (vascular endothelial growth factor), decorated onto the lumen of the graft s. One such study employed EDC chemistry on glutaraldehyde soaked PTFE graft s, with subsequent treatment with HAS bonds and covalent chemistry to bind VEGF onto the lumen to allow for endothelial cell migration and proliferation 12 . Another study used collagenous scaff olds which were treated with heparin benzalkonium chloride complex (HBAC) cross-linked via EDC chemistry to successfully prevent clotting of small diameter graft s in pigs 49 . In a recent study from our lab, heparin was employed to coat SIS by means of EDC-NHS chemistry, followed by immobilization of VEGF via binding to the heparin binding domain. Th ese graft s exhibited high patency rates in the high fl ow environment of ovine carotid arteries and produced fully endothelialized, functional arteries as soon as one month post-implantation 50 . Unlike antibodies which have also been applied to capture EPCs from the host bloodstream 51, 52 , VEGF enhances the survival, proliferation and cell spreading of captured progenitors [53] [54] [55] [56] , making it a more attractive option for functionalizing TEBVs.
Design simplifi cation and cell-free grafts
Cell-based technologies depend on patient cell harvest and expansion, bioreactor culture and preconditioning, which makes the manufacture of TEVGs a lengthy and expensive process 4, 7 . Furthermore, primary adult cells or stem cells isolated from patients exhibit limited expansion potential, which further declines with patient age. To overcome these limitations, several groups including our own have developed completely acellular vascular graft s that may be available off -the-shelf and on demand and suitable as an arterial or venous replacement for treatment of cardiovascular disease.
An important advancement in engineering the next generation of TEBVs will be design simplifi cation, which will make off -the-shelf grafts available for implantation 4 . We have recently shown in our laboratory that SMCs are not required in the medial layer of a vascular graft , with the correct choice of biomaterial 37 . In this context, biomaterial properties such as porosity become critical for graft patency and remodeling 20, 57, 58 . Another study used a biodegradable elastomer that was replaced by a neoartery in a rat animal model 59 . ECs have been replaced by growth factors and antibodies which are capable of capturing host circulating EPCs 50 . Zhou et al. have utilized heparin and VEGF to replace the endothelial lining, and have shown successful implantation in a canine arterial model 60 .
In a recent case-study, L'Heureux and colleagues have used their "lifeline graft s" off -the-shelf by freeze-drying technique as dialysis access graft s 6 . Lifeline graft s are tubularized self-assembled cell sheets, which can be frozen and thawed a few days before the procedure and endothelialized with the patients' own cells 6 . In another human case study of a 4-year-old girl, poly caprolactone-polylactic acid (PCL-PLA) copolymer seeded with vascular SMCs isolated from the patients' own peripheral vein was used as a TEBV to replace a pulmonary artery 5 . Shinoka and colleagues have used graft s made in similar fashion in human clinical trials with success 61 . Niklason and colleagues at Humacyte have also developed cell-free graft s starting from traditional cell-based tissues. Th ey employed banked human smooth muscle cells and pulsatile bioreactors to culture PLGA-based vascular constructs for 7-10 weeks in order to produce enough ECM to better mimic the in vivo environment. Th en the graft s were decellularized prior to storage and surgery 22, 62 . Th e cell-free graft s were employed in phase-2 single-arm clinical trials as upper arm brachial-to-axillary-straight graft s, where their secondary patency was reported to be 89% at 12 months post-implantation 63 . However, a major cause for concern remains that the primary patency was only at 63% at 6 months and dropped to 28% at 12 months 63 . Th is was mainly because of the propensity of cell-free graft s to occlude, which might be attributed to the lack of a healthy, confl uent endothelium.
Our group has recently reported the development of cell-free graft s that were implanted successfully in a large, preclinical animal model. These grafts were based on SIS that was functionalized sequentially with heparin and VEGF, in order to prevent thrombosis and attract endothelial progenitor cells. When implanted as interpositional graft s in the carotid arteries of an ovine model, they exhibited 92% patency rate 50 . By employing VEGF, which captures progenitor cells from the bloodstream, these graft s were fully endothelialized within a month, as evidenced by immunostaining for mature endothelial markers such as vWF, CD144 and eNOS. Th e vascular wall also showed signifi cant infi ltration of host cells expressing smooth muscle proteins and exhibiting vascular contractility in response to vasoconstrictors and dilators. Aft er three months, the endothelium aligned in the direction of fl ow and the medial layer comprised of uniformly distributed and circumferentially aligned smooth muscle cells closely resembling native carotids. Th is study demonstrated the feasibility of engineering cell-free vascular conduits that can serve as "off -the-shelf " vascular graft s to treat cardiovascular disease.
DECELLULARIZATION STRATEGIES
Th e goal of decellularization is to eff ectively isolate the ECM of a biological tissue from its immunogenic materials such as cellular and nuclear contents. While any xenogeneic or allogeneic cellular antigens are very likely to trigger an adverse immune response by the host, leading to graft rejection, the composition of the ECM is similar between species. Th e ECM is a protein-abundant microstructure comprised of glycoproteins, proteoglycans, glycosaminoglycans and structural proteins such as collagens, elastin, fi bronectin and laminin providing a scaff old that enables cell adhesion, proliferation and diff erentiation 64 . Th e microstructure and morphology of the ECM vary between organs suggesting that decellularization protocols that have been developed for one organ/tissue may not be as eff ective for others 65 . For instance, while Triton X-100 has been an eff ective detergent for removing superfi cial cellular and nuclear material from heart valves, it was not as eff ective in decellularizing tendons, ligaments and blood vessels 66 . For our purpose, we will focus our discussion on strategies employed to decellularize tissues for use in vascular tissue engineering.
Small diameter graft s (< 6 mm) derived from synthetic materials have shown poor clinical performance as they continue to exhibit low patency and high rates of thrombus formation. Additionally, studies have shown that they are highly susceptible to intimal hyperplasia at the sites of anastomosis 67, 68 . Th e current challenges facing synthetic graft s may be attributed to the mismatches in mechanical properties -specifi cally compliance -between the native and synthetic vessels and the surface chemistry that governs important cellular functions such as infi ltration and proliferation 69, 70 . Alternatively, decellularization of biological tissues yields scaff olds that closely resemble native ECM in composition and micro-anatomical structure, and are therefore more suitable for vascular graft ing. As the removal of cellular material is typically accomplished by physical or chemical treatments, enzymatic agents or a combination thereof, the process involves steps that may aff ect the structure and/or composition of the ECM. Despite such drawbacks, decellularization protocols are more eff ective than synthetic biomaterial strategies in producing scaff olds mimicking the composition and structure of native ECM. Consequently, many research groups have been investing time and eff ort in developing decellularization strategies that maintain the biochemical composition and structural integrity of native ECM, thereby preserving its function and suitability as vascular implant.
A standard decellularization approach, in general, involves the extraction of tissues through dissection, which is followed by with a suitable buff er and treatment with antibiotic and antimicrobial agents (penicillin, streptomycin and amphotericin B) in order to keep the tissues hydrated and resistant to bacterial growth. Th e tissues may then be subjected to physical treatments, detergents and/or enzymatic agents to remove cellular content and chromosomal DNA. Subsequently, the decellularized scaff olds may be seeded with cells, or functionalized with biological factors and implanted in vivo. In an attempt to optimize decellularization and ensure consistency of the fi nal product, various groups have opted to automate the process by developing relatively simple devices that integrate all the desired chemical and/or physical processes and may involve several cycles and the use of diff erent solvents [70] [71] [72] . Th ese steps are described in more detail below.
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Physical treatments
Physical treatments are intended to lyse cells by releasing cytoplasmic material, however, they tend to be insufficient at removing all the immunogenic content, which is why they are oft entimes coupled with chemical detergents and/or enzymatic agents to remove remaining cellular debris. Common physical treatments involve sonication, pressure, shear forces, freezing and thawing 73 . Hypotonic and hypertonic solutions have also been found to be eff ective at mediating the cell lysing process 71 . Azhim and coworkers have performed studies on decellularization of porcine aorta via sonication at the luminal side while immersed in 2% SDS (sodium dodecyl sulfate) solution 74 . Th eir fi ndings showed that sonication at 15 W removed their DNA content with insignificant change in mechanical properties 75 . Despite the predominant tendency toward chemical washes and enzymatic digestion processes, some groups claim to have developed novel physical decellularization approaches that do not require the action of harsh chemicals or enzymes 76 , thereby preserving the integrity of the tissues. Th e experimental setup involves suspending aortic porcine blood vessels in saline solutions followed by exposure to high pressure, under temperature control to avoid freezing that may cause rupture of collagen fi bers. Good temperature-control resulted in material with signifi cantly less DNA content, better preserved ECM structure, and superior mechanical properties. No infl ammatory response was observed upon implantation and the lumen was repopulated by the host's endothelial cells, rendering the graft s patent for up to 24 weeks in vivo.
Chemical treatments
A wide variety of chemical treatments have been reported in the literature ranging from alkaline and acidic solutions to ionic and non-ionic detergents 73 . Each of these detergents has their own unique way of altering the structure and components of the cells as well as the three-dimensional structure of the ECM. Acid and alkaline-based treatments are used to dissociate cell membranes and intracellular organelles. Acid solutions, in particular, have the potential to denature and solubilize nucleic acids. Nevertheless, drastic changes in pH affect the morphology and functionality of biological tissues by disrupting the surface chemistry and solubilizing free amine residues and activity of growth factors and glycosaminoglycans. The same effect is observed when using ionic detergents, such as sodium deoxycholate (DCA) and SDS. Therefore, these detergents are used in moderate concentrations.
On the other hand, non-ionic detergents like Triton X-100, are superior in preserving the architecture of the ECM since they mostly target lipid-lipid interactions, but they are not as effi cient in removing DNA. Zwitterionic detergents, which exhibit the properties of both ionic and non-ionic detergents are harsher to the ECM structure relative to Triton X-100, but they do not lead to signifi cant loss of mechanical properties. Th e most popular zwitterionic detergent that has been employed to decellularize arteries is 3-[(3 cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Both Triton X-100 and CHAPS elute the glycosaminoglycans present in biological tissues 71 . Finally, EDTA and EGTA have also been included in decellularization protocols to facilitate cell removal by chelating calcium and magnesium and disrupt cell-cell and cell-matrix adhesion.
Enzymatic treatment
Enzymes are, without a doubt, a powerful decellularization tool due to their high specifi city and can be used to digest nucleic acids (DNA and RNA) or to remove unwanted ECM residue. Trypsin and nucleases are consistently employed in decellularization protocols. Fetal bovine serum (FBS) is a good source of nucleases. In fact, incubation of decellularized tissues in FBS-containing media results in low levels of β-actin, major histocompatibility complex (MHC) and DNA content 77 .
Combination treatments
Th e combination of physical, chemical and enzymatic treatments may be required for optimal decellularization and may also reduce the need of concentrated chemicals or severe agitation. In one study, Gui and coworkers successfully developed functional, small-diameter, tissue engineered vessels derived from human umbilical cords, using a novel decellularization approach based on a combination of zwitterionic and ionic detergents, and enzymatic treatment 78 . The two-step decellularization process involved treatment with CHAPS buff er, followed by treatment with SDS. Th e samples were further incubated in endothelial growth media-2 (EGM-2) containing 12% fetal bovine serum with the required enzymatic cocktail to digest unwanted cellular debris. Th is strategy produced promising results as the decellularized graft s maintained their ECM content and promoted adhesion of human umbilical endothelial cells (HUVECs) in vitro. Upon implantation into nude rats, these cell-free graft s exhibited less intimal hyperplasia as compared to non-decellularized control vessels and promoted smooth muscle cell adhesion to the vascular wall and robust collagen matrix deposition. However, patency was poor (only 30% at 4 weeks) as these decellularized implants were thrombosed by 8 weeks postoperatively, most likely due to lack of an endothelial monolayer.
Another strategy for decellularizing ovine arteries employed treatment with 0.05% Trypsin, 0.02% EDTA and 1% antibiotic/antimycotic (AA) in PBS, followed by treatment with 1% Triton X-100, 1% AA and enzymatic treatment with DNase and RNase 79 . Th e treated arteries contained negligible amount of DNA and were completely devoid of laminin. On the other hand, the ECM structure and collagen and fi bronectin content were preserved as shown by scanning electron microscopy and immunostaining. Interestingly, the decellularized arteries supported adhesion of human MSCs and exhibited mechanical properties e.g. tensile strength and compliance that were statistically similar to those of untreated control arteries. In contrast, while effective as a decellularization agent, 1% SDS had a negative eff ect on the mechanical properties of decellularized tissues, as shown in the same study 79 .
An unconventional, yet quite successful, decellularization protocol for SIS was proposed by Cook Biotech (US patent #6,206,931). Porcine small intestines were isolated from fully grown adult pigs and subjected to disinfection with 0.5% (v/v) perpropionic acid, 0.3% (v/v) peracetic acid or 5% (w/v) chlorhexidine digluconate in ethanol. Further washes were carried out in hypotonic solution of hydrogen peroxide, which enhanced the removal of pathogens, pyrogens and blood constituents, while maintaining the porosity and structural integrity of the material. Th e submucosal layer was then isolated with the aid of a casing machine and used to prepare SIS-based vascular graft s, which showed slightly lower compliance than the average native carotid artery and signifi cantly higher burst pressure than the average systolic pressure 80 . Such mechanical properties made them highly suitable for use as arterial replacement graft s.
Devices for decellularization
Decellularization devices have been developed to automate and accelerate the process while providing consistent results. One group developed a device to decellularize swine abdominal aorta and carotid arteries using DCA and DNase I treatments 69, 81 . Th e device was composed of one reservoir and pump for each step of fl uid exchange, a decellularization chamber and a pump to draw fl uids into a waste container. Process parameters such as fl uid fl ow rates, temperature and shaking rate were controlled by the control unit and the whole process was repeated for a total of 4 cycles. Th e resulting decellularized arteries exhibited well preserved ECM structure and similar Young's modulus and UTS (ultimate tensile strength) as native arteries. However, some residual DNA was still present in the tissues. A subsequent study optimized the device further to provide longitudinal and radial strain under sterile conditions using two pumps, a heat exchanger TECHNOLOGY l VOLUME 5 • NUMBER 1 • MARCH 2017 © World Scientific Publishing Co. and a microcontroller-based unit 70 . Vascular graft s produced with this device were seeded with human iliac artery endothelial cells (hIAEC), and implanted in the iliac arteries of pigs where they remained patent for up to 70 days post-implantation. Interestingly, hIAEC were replaced by host endothelial cells and smooth muscle cells were observed to migrate from the adventitia to the medial layer of the vessel wall.
Another approach utilized a perfusion-driven process that could successfully decellularize tissues using low concentrations of chemicals and short exposure times 71 . Vessels harvested from the placenta were attached to a perfusion capillary and assembled to a recirculation system with a peristaltic pump, which allowed for application of reverse osmotic pressure for cell lysis. Th e process started with cell lysis via osmotic pressure using hypotonic (0.4% NaCl) and hypertonic (1.2% NaCl) saline solutions, followed by washes with a solution containing 1% Triton X-100 and 0.02% w/w EDTA in PBS and treatment with DNase I and 0.1% w/v of peracetic acid (PAA) prior to being stored at 4°C in PBS. Th e process preserved the collagen and glycosaminoglycan (GAG) content, thereby promoting endothelial cell attachment and preserving the mechanical properties (elastic modulus and UTS) of the decellularized grafts. Finally, application of pulsatile force during decellularization of human umbilical cords signifi cantly reduced the time required for complete removal of cellular material (only 3 hours), but in vivo performance was not determined 72 .
Decellularization of cell-based tissue engineered vascular grafts
In addition to native tissues, some groups developed processes to decellularize tissue engineered vascular graft s. Similar to prior work with skin tissue substitutes (Dermagraft , Advanced Tissue Sciences 82,83 ), Humacyte Inc. decellularized tissue engineered vascular graft s (Lifeline) that have been used recently in clinical trials 63 (IND#15263, FDA). To this end, they engineered vascular tissues using polyglycolic acid scaffolds that were populated with banked human smooth muscle cells and cultured in bioreactors for 7-10 weeks, long enough time to produce adequate amounts of ECM and remodel the polymeric scaff old to a composition that closely resembles the native vessel wall. Th e graft s were then decellularized and were either implanted directly to replace large diameter grafts 62 ; or following endothelialization of their lumen to replace small diameter graft s, which are known to occlude more readily 39, 84 . These grafts were also implanted as arteriovenous fi stulas for use in dialysis patients. In the interim report 63 , the primary patency rate at 12 and 24 months post-implantation was only 28% and 15%, respectively, requiring surgical intervention to restore patency. Subsequently, the secondary patency rate remained high at 80% for 24 months, enabling long-term clinical use of these graft s.
Th is technique has also been employed by another group that employed fi brin hydrogels as scaffolds 29, 85 . These scaffolds were seeded with allogeneic ovine dermal fibroblasts, which were integrated into the fibrin gels during fi brinogen polymerization with thrombin. Aft er static culture for 2 weeks, these were transferred to a custom-designed pulsatile bioreactor for 5 weeks to enable graft maturation. Th e resultant tubes were then decellularized with SDS, and Triton X-100 and subjected to nuclease treatments. Th ese decellularized fibrin-based grafts were implanted into lambs as pulmonary artery substitutes and the animals were allowed to grow to adulthood (1 year) . Th e results showed that the volume and diameter of the implanted vessel increased with the size of the host, indicating somatic growth potential of these graft s 86 .
Th is strategy obviates the need for autologous cells and can provide off -the-shelf graft s for clinical use. However, the costs and processing time associated with cell isolation and banking, bioreactor culture and decellularization is signifi cant, necessitating development of strategies that eliminate the need for cells and bioreactors. Such a strategy may entail building "neo-vessels" in situ starting with cell-free graft s. Th is alternative approach may require functionalization of the lumen in order to prevent occlusion and attract host endothelial cells to ensure long-term patency. In addition, functionalization may attract the patients' own cells to form the smooth muscle medial layers required for contractile function.
FUNCTIONALIZATION STRATEGIES
Th e major cause of failure in synthetic and biomaterial-based engineered vessels is occlusion by formation of thrombus 3 . It has long been known that the presence of certain peptide sequences e.g. REDV (Arg-Glu-Asp-Val) promote a non-thrombogenic surface and at the same time favor endothelial cell attachment, spreading and proliferation 87 . Prevention of thrombus formation has since then been attempted mostly by heparin coating or bonding that activates anti-thrombin II (ATII), thereby inhibiting the thrombin clotting cascade 60, 88 . Previous studies used heparin that was ionically or electrostatically bound to the polymer and was designed to be released over time in order to maintain patency. In one study, PCL and Chitosan (positively charged) were co-electrospun, in order to make a scaff old with net positive charge so that it binds negatively charged heparin 89 . Once implanted into the rat abdominal aorta, these graft s remained patent for 1 month, most likely due to the elution of heparin from the graft 89 . A similar approach was used with a diff erent composite material made of PCL, polyvinyl alcohol (PVA) and gelatin, in which the fi bers degraded to release heparin in vivo in a controlled manner 90 . Another biodegradable and positively charged material, polymerized allylamine (PAA) has also been used to bind heparin electrostatically, promoting attachment and physiological function of HUVECs as evidenced by release of NO and prostaglandin 89 .
While these studies have shown short-term patency, others have proposed that covalent bonding of heparin on the lumen may be preferred due to concerns with heparin-induced thrombocytopenia (HIT), caused by high levels of heparin in the blood and prompting regulatory concerns with heparin-eluting graft s and stents 91 . Indeed, covalent bonding of heparin to graft s by cross-linking or amide linkages has been proven to be eff ective in maintaining patency in several models. Immobilization of heparin can be easily achieved by EDC chemistry or glutaraldehyde crosslinking 49, 92 . Heparin with benzalkonium chloride complex could be bound onto the a decellularized intestinal collagen layer by EDC chemistry, which performed adequately as an interpositional graft in a rabbit artery model, but required an additional collagen layer in the lumen in order to attract endothelial cells for longer term patency 49 . Comparable studies utilized fi bronectin in addition to covalent bonding of heparin 93 , addition of gelatin or chitosan into the scaff old 92 , addition of specifi c peptides and growth factors [94] [95] [96] , and antibodies for capture of circulating progenitor cells 52 . However, binding of cells to antibodies blocked the function of the targeted receptor, thereby reducing the function of the newly-formed endothelium 52 . Recently, poly(carboxybetaine methacrylate) or PCMBA was functionalized with a peptide that is known to capture and support the growth and spread of EPC but not mature endothelial cells such as HUVECs 95 .
Similarly, growth factors such as stromal derived factor-1α (SDF-1α) and VEGF have been used to capture EPCs. SDF-1α has been used in two recent studies to capture EPCs, aft er implantation in the rat aorta 96 or in the sheep carotid artery 94 . VEGF has also been shown to capture EC even under fl ow 30,50,55,60 , suggesting that it may be effi cient in endothelializing cell-free graft s. Interestingly, two in vivo studies, reported that immobilized heparin was insuffi cient in maintaining long term patency (>1 month) and required the presence of VEGF, which was bound via the heparin binding domain 50, 60 . Our laboratory recently demonstrated the ability of heparin-bound, surface immobilized VEGF to capture endothelial cells (EC) under fl ow in vitro 56 . Subsequently, we employed this strategy to immobilize VEGF on the surface of a natural biomaterial, namely Small Intestinal Submucosa (SIS) to engineer a cell free vascular graft . Our A-TEV (A-cellular Tissue Engineered Vessel) was made with tubular laminated SIS, with heparin conjugated via EDC-NHS chemistry and subsequent coating of VEGF, which is covalently bound to heparin via its HBD (heparin binding domain). See Fig. 1 .
Th ese A-TEVs have been tested in a preclinical ovine carotid model for up to 3 months 50 . To date we have tested n = 25 sheep with 92% patency. A functional confl uent endothelium was formed in the lumen of these graft s as early as 1 month post-implantation, as evidenced by scanning electron microscopy and immunohistochemistry. Remodeling also occurred within the host, through an inflammation-mediated macrophage invasion that was shown to be necessary for host-cell infiltration, remodeling and ultimately, development of biological function 3, [40] [41] [42] . Although SIS is porcine in its origin, the nucleic acid content remaining aft er processing is negligible (< 0.2 ng/mg; see Patent #6,206,931, COOK Biotech). Th erefore, macrophage invasion is most likely part of the normal wound healing response that may be facilitated by the structure and porosity of this natural scaff old 97 . In addition to the capability for self-endothelialization, the vascular wall was populated by host smooth muscle cells, which were functional and responded to vaso-active agonists. Aft er 3 months, the graft s not only resembled the native carotid in structure and function, but also in mechanical properties such as mechanical strength and compliance.
CONCLUSIONS
Overall, development of strategies to engineer functional and implantable, cell-free vascular graft s may overcome many of the issues associated with the presence of cells, including immune rejection of allogeneic cells, challenges associated with senescence and expansion of autologous cells (especially from older patients), long-culture times in bioreactors, and the high cost of cellular therapies. Since the feasibility of these graft s has already been demonstrated in large animal models, the fi eld will gain signifi cant momentum by successful testing of these graft s in human clinical trials.
